Document is current
Any future updates will be listed below
-
Authors
Howe, Matthew D.
Britton, Karysa J.
Joyce, Hannah E.
Menard, William
Emrani, Sheina
Kunicki, Zachary J.
Faust, Melanie A.
Dawson, Brittany C.
Riddle, Meghan C.
Huey, Edward D.
Janelidze, Shorena
Hansson, Oskar
Salloway, Stephen P.
-
Funding
Funding for this research was provided by:
National Institute of Mental Health (2R25MH101076-06A1)
National Institute on Aging (R01AG079241, R01AG083740, 2P01AG051449-06)
Alzheimer's Association (SG-23-1061717)
- License Information
-
More Information
Article History
Received: 14 December 2023
Accepted: 26 June 2024
First Online: 6 July 2024
Declarations
:
: All study procedures adhered to the ethical standards of the Butler Hospital Institutional Review Board (IRB #2108–001, #1604–001) and the Helsinki Declaration of 1975. All participants provided written consent to participate in the study, to undergo all study procedures and to publish deidentified data collected as part of study participation.
: Not applicable.
: Neither the drug manufacturer (Biogen, Inc.) nor the assay manufacturer (Eli Lilly, Inc.) had any direct role in the design and conduct of the study; in the collection, analysis, and interpretation of data; in the preparation of the manuscript; or in the review or approval of the manuscript.M. Howe: <i>None to disclose.</i> K. Britton: <i>None to disclose.</i> H. Joyce: <i>None to disclose.</i> S. Emrani: <i>None to disclose.</i> Z. Kunicki: <i>None to disclose.</i> W. Menard: <i>None to disclose.</i> M. Faust: <i>None to disclose.</i> B. Dawson: <i>None to disclose.</i> M. Riddle: <i>Dr. Riddle receives salary support as a site principal investigator for Biogen (EMBARK, ENVISION, CELIA), Eli Lilly (TRAILBLAZER-6), Janssen (AUTONOMY) and Eisai (BAN 2401).</i> E. Huey: <i>None to disclose.</i> S. Janelidze: <i>None to disclose.</i> O. Hansson: <i>Dr. Hansson has acquired research support (for the institution) from ADx, AVID Radiopharmaceuticals, Biogen, Eli Lilly, Eisai, Fujirebio, GE Healthcare, Pfizer, and Roche. In the past 2 years, he has received consultancy/speaker fees from AC Immune, Amylyx, Alzpath, BioArctic, Biogen, Bristol Meyer Squibb, Cerveau, Eisai, Eli Lilly, Fujirebio, Merck, Novartis, Novo Nordisk, Roche, Sanofi and Siemens.</i> S. Salloway: <i>Dr. Salloway has provided consultation to Biogen, Eisai, Avid, Lilly, Genentech, and Roche; he was a site principal investigator on the PRIME and ENGAGE studies and co-chair of the Investigator Steering Committee for the ENGAGE study. Dr. Salloway is an author on the Appropriate Use Recommendations (AUR) for Aducanumab and Lecanemab. Butler Hospital has received research grants from Biogen, Eisai, Avid, Roche, Genentech, Janssen and Lilly.</i>
